NewAmsterdam appoints McKenna and Joustra to board; Slootweg resigns

NewAmsterdam Pharma Co N.V.

Sander Slootweg resigned from the Board effective July 16, 2024; no disagreement cited.
Wouter Joustra (Forbion general partner) and Mark C. McKenna (Mirador CEO) appointed as temporary non-executive directors.
McKenna granted options for 72,500 ordinary shares at $18.81 per share, vesting over 3 years.
McKenna also joins audit and compensation committees; Joustra brings capital markets and venture experience.
Appointments effective immediately; formal ratification expected at next annual general meeting.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sander Slootweg

Director

NAMS · NewAmsterdam Pharma Co N.V.

Effective: 2024-07-16
Filed: July 18, 2024, 7:59 PM ET

On July 16, 2024, Sander Slootweg notified NewAmsterdam Pharma Company N.V. (the “Company”) of his decision to resign as a member of the Company’s board of directors (the “Board”) effective immediately.

Appointed

Wouter Joustra

Director

NAMS · NewAmsterdam Pharma Co N.V.

Effective: 2024-07-16
Filed: July 18, 2024, 7:59 PM ET

On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.

Appointed

Mark C. McKenna

Director

NAMS · NewAmsterdam Pharma Co N.V.

Effective: 2024-07-16
Filed: July 18, 2024, 7:59 PM ET

On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sander Slootweg resigned as Director at NewAmsterdam Pharma Co N.V..

Action: resigned
Role: Director

Exact text from the filing

On July 16, 2024, Sander Slootweg notified NewAmsterdam Pharma Company N.V. (the “Company”) of his decision to resign as a member of the Company’s board of directors (the “Board”) effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Wouter Joustra was appointed as Director at NewAmsterdam Pharma Co N.V..

Action: appointed
Role: Director

Exact text from the filing

On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark C. McKenna was appointed as Director at NewAmsterdam Pharma Co N.V..

Action: appointed
Role: Director

Exact text from the filing

On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.

View on SEC.gov

NewAmsterdam Pharma Co N.V. filing history →

Source: SEC EDGAR

accession 0001193125-24-180754

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.